In both models, anti-CD4 antibody treatment was associated with a trend toward tumor reduction; however, statistical significance was reached only in the mock group, possibly due to inter-animal biological and experimental variability in the ULBP2 group. This evidence concerns the gene ULBP2 and neoplasm.